(Q57762740)

14

object named as

Tawesak Tanwandee

0 references

author name string

Guohong Han

2

0 references

Richard S. Finn

3

0 references

Ronnie T.P. Poon

4

0 references

Jean-Frederic Blanc

5

0 references

Lunan Yan

6

0 references

Jijin Yang

7

0 references

Ligong Lu

8

0 references

Won-Young Tak

9

0 references

Xiaoping Yu

10

0 references

Joon-Hyeok Lee

11

0 references

Shi-Ming Lin

12

0 references

Changping Wu

13

0 references

Guoliang Shao

15

0 references

Ian B. Walters

16

0 references

Christine Dela Cruz

17

0 references

Valerie Poulart

18

0 references

Jian-Hua Wang

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

19

0 references

language of work or name

English

0 references

publication date

29 September 2014

0 references

published in

Hepatology

0 references

volume

60

0 references

issue

5

0 references

page(s)

1697-1707

0 references

cites work

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease

21 January 2018

1 reference

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

21 January 2018

1 reference

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast gro

21 January 2018

1 reference

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.

21 January 2018

1 reference

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

21 January 2018

1 reference

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

21 January 2018

1 reference

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

21 January 2018

1 reference

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

Chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma

1 reference